What's hot

View all perspectives
      APEX Phase 3b trial: #guselkumab (Q4W or Q8W) reduces joint damage in #PsA
      ✅ ACR20: 67–68% vs 47% (PBO)
      ✅ ↓radio

      Mrinalini Dey DrMiniDey

      3 months ago
      APEX Phase 3b trial: #guselkumab (Q4W or Q8W) reduces joint damage in #PsA ✅ ACR20: 67–68% vs 47% (PBO) ✅ ↓radiographic progression (vdH-S: 0.55/0.54 vs 1.35) No new safety signals identified. @RheumNow #EULAR2025 #LB0010 https://t.co/LLN1TXvOC3
      #GameChanger

      Subset analysis of #CTD Pts with
      Progressive pulmonary fibrosis
      #PPF
      Ok background #nintedanib 1/3
      ❎lun

      Janet Pope Janetbirdope

      3 months ago
      #GameChanger Subset analysis of #CTD Pts with Progressive pulmonary fibrosis #PPF Ok background #nintedanib 1/3 ❎lung IS 2 doses #PDE4Bi #nerandomilast vs #PBO each dose ⬇️worsening #FVC vs PBO ⬇️lung events - hospital ⬇️death GI A/E #EULAR2025 Latebreakers I @RheumNow https://t.co/PWKEnpyyMN
      Genicular artery embolisation is like so many interventions in MSK medicine:
      early promise with smaller RCT & observ

      David Liew drdavidliew

      3 months ago
      Genicular artery embolisation is like so many interventions in MSK medicine: early promise with smaller RCT & observational data, but the later, more robust data doesn’t show the same benefit. If you do meta-analyses of all these data, you mix good with bad #EULAR2025 @RheumNow https://t.co/K1tN9KX8rq
      Management and prognosis of RP by @Lupusreference
      1. Pts with mild disease respond to GCs
      2. NSAIDs/colchicine good alt

      Adela Castro AdelaCastro222

      3 months ago
      Management and prognosis of RP by @Lupusreference 1. Pts with mild disease respond to GCs 2. NSAIDs/colchicine good alternatives 3. Most common biologics used: TNFi and IL6i 4. Consider CYP in life threatening dz/ICU pts 5. Dynamic CT assess tracheal collapse. 6. PET-CT can ≠ https://t.co/PNUecMZvkT
      Results from open label
      extension of BE-OPTIMAL:
      -Bimekizumab in bDMARD naïve pts showed sustained efficacy after 1y un

      Adela Castro AdelaCastro222

      3 months ago
      Results from open label extension of BE-OPTIMAL: -Bimekizumab in bDMARD naïve pts showed sustained efficacy after 1y until 3y. -No significant major tolerability issues or major SE. abstract #POS1294 #EULAR2025 @RheumNow https://t.co/VAEiciCR1z
      ICI-PMR irAEs are sometimes underestimated compared to inflamm arthritis, but why?

      ICI-IA and ICI-PMR look different, b

      David Liew drdavidliew

      3 months ago
      ICI-PMR irAEs are sometimes underestimated compared to inflamm arthritis, but why? ICI-IA and ICI-PMR look different, but at @HSpecialSurgery, steroid needs and disease impact for both are basically the same. Let’s not devalue either @lovetolearn27 #EULAR2025 POS1200 @RheumNow https://t.co/NVq2tpjvdu
      #EULAR2025 Abstr#POS0301 Real World Multicentre study in Italy reported higher proportion of CRR at 6-mth & Lower GC

      Md Yuzaiful Md Yusof Yuz6Yusof

      3 months ago
      #EULAR2025 Abstr#POS0301 Real World Multicentre study in Italy reported higher proportion of CRR at 6-mth & Lower GC in people with #lupus nephritis (~96% Class III, IV or Mixed with V) treated with Belimumab+SOC vs matched cohort on SOC. Predicted by early BEL use @RheumNow https://t.co/D6e2qo9NRL
      ✅Exciting results from POETYK PsA-1: -Deucravacitinib (TYK2i) in PsA
      -ACR 20 was achieved in significantly more patie

      Adela Castro AdelaCastro222

      3 months ago
      ✅Exciting results from POETYK PsA-1: -Deucravacitinib (TYK2i) in PsA -ACR 20 was achieved in significantly more patients treated with deucravacitinib vs placebo at W16 (54.2% vs 34.1%; P < 0.0001), with similar results for ACR 50 and ACR 70 -Also met 2dary endpoints. -Post hoc https://t.co/S4DhovMCma
      Hidradenitis suppurativa is newer to us in rheumatology, but it seems like inflamm arthritis is a problem - at least to

      David Liew drdavidliew

      3 months ago
      Hidradenitis suppurativa is newer to us in rheumatology, but it seems like inflamm arthritis is a problem - at least to a similar extent as in psoriasis. Time for us to look for it & to see what therapies like IL-17 inhibitors do for this arthritis #EULAR2025 POS1237 @RheumNow https://t.co/b5EQdDEAhq
      Social disparities in rheumatology @RheumNow #EULAR2025
      ~70% of outcomes are determined by Social determinants of healt

      Bella Mehta bella_mehta

      3 months ago
      Social disparities in rheumatology @RheumNow #EULAR2025 ~70% of outcomes are determined by Social determinants of health Modifiable factors ? Maybe? https://t.co/UfC2nQ5Azy
      @RheumNow Achieving health equity is the goal
      1.4% of GDP is lost in health inequity in EU https://t.co/50M4SfuxvX

      Bella Mehta bella_mehta

      3 months ago
      @RheumNow Achieving health equity is the goal 1.4% of GDP is lost in health inequity in EU https://t.co/50M4SfuxvX
      How much of the health outcomes are related to social determinants?

      🔺️Up to 75%!

      Disaster Medicine Session
      Social

      Nelly ZIADE 🍀 Nellziade

      3 months ago
      How much of the health outcomes are related to social determinants? 🔺️Up to 75%! Disaster Medicine Session Social disparities and impact on outcomes Dr Kate Webb #EULAR2025 @RheumNow https://t.co/0Ahbf79Nbx
      #EULAR2025 Abstr#LB0007 Two’s Company, Three’s a Crowd! In 5 #SLE pts treated with CC312, a novel CD19/CD3/CD28 tri-

      Md Yuzaiful Md Yusof Yuz6Yusof

      3 months ago
      #EULAR2025 Abstr#LB0007 Two’s Company, Three’s a Crowd! In 5 #SLE pts treated with CC312, a novel CD19/CD3/CD28 tri-specific ab in dose escalation showed rapid & B-cell depletion & all achieved SRI-4. No =>G2 CRS or ICANS. USP: off-the-shelf & overcome T-cell exhaustion @RheumNow https://t.co/6DZRj09JEQ
      Low disease activity more difficult to achieve in vulnerable populations.
      All rheumatic diseases - #RA #PsA #AS
      initia

      Bella Mehta bella_mehta

      3 months ago
      Low disease activity more difficult to achieve in vulnerable populations. All rheumatic diseases - #RA #PsA #AS initiating DMARDs takes longer in these population #EULAR2025 @RheumNow https://t.co/voIivshKRt
      What do we know about disparities in #SLE
      - worse in women
      - worse in non white populations
      - have lower quality of car

      Bella Mehta bella_mehta

      3 months ago
      What do we know about disparities in #SLE - worse in women - worse in non white populations - have lower quality of care in vulnerable populations - have worse outcomes in vulnerable populations #EULAR2025 @rheumnow Diagnosis itself is difficult in communities with poor access https://t.co/pcUaJ0eK65
      How well do you know this week's rheumatology news?
      Take the rheumIQ quiz
      Take the RheumIQ Quiz

      Podcasts

      • EULAR 2025 Rheumatology RoundUp Hosted by Dr. John J. Cush and Dr. Arthur Kavanaugh
      • EULAR 2025 - Day 9 podcast
      • EULAR 2025 - Day 8 podcast

      Catch up on Conference Podcasts

      ×